AMPH Q1 2022 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$120M+16.8% YoY

Gross Profit

$56M46.4% margin

Operating Income

$22M18.0% margin

Net Income

$24M20.1% margin

EPS (Diluted)

$0.47

QoQ Revenue Growth

-0.4%

Cash Flow

Operating Cash Flow

$51M

Free Cash Flow

$45M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$716M

Total Liabilities

$237M

Stockholders' Equity

$480M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$120M	$103M	+16.8%
Gross Profit	$56M	$45M	+24.2%
Operating Income	$22M	$10M	+109.7%
Net Income	$24M	$5M	+381.1%

Revenue Segments

Research and development services

$600,000100%

Geographic Segments

UNITED STATES

$117M97%

FRANCE

$2M2%

CHINA

$933,0001%